Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...
The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...
An experimental HIV prevention pill being developed by Merck could be mass produced for less than $5 per patient a year ...
U.S. FDA accepts and grants Priority Review for the Biologics License Application for ifinatamab deruxtecan. The application ...
Despite the president’s plan to lower prescription medicine costs, the price of many of the most expensive drugs — including ...
The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that ...
A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of ...
Zacks Investment Research on MSN
Will Keytruda continue to aid Merck's top line in Q1 earnings?
A significant share of Merck’s MRK revenues is derived from the oncology portfolio, led by its blockbuster PD-L1 inhibitor, ...
Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...
PM UTC It will lose patent exclusivity within the next two years, but Merck has earned approval for a new, subcutaneous ...
WASHINGTON - U.S. health regulators on Thursday authorized Merck’s COVID-19 pill, known as molnupiravir — the second medication approved for at-home use to battle the rapidly-spreading omicron variant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results